Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is a form of progressive interstitial lung disease with unknown etiology. Due to a lack of effective treatment, IPF is associated with a high mortality rate. The hallmark feature of this disease is the accumulation of activated myofibroblasts that excessively deposit extracellular matrix proteins, thus compromising lung architecture and function and hindering gas exchange. Here we investigated the origin of activated myofibroblasts and the molecular mechanisms governing fibrosis formation and resolution. Genetic engineering in mice enables the time-controlled labeling and monitoring of lipogenic or myogenic populations of lung fibroblasts during fibrosis formation and resolution. Our data demonstrate a lipogenic-to-myogenic switch in fibroblastic phenotype during fibrosis formation. Conversely, we observed a myogenic-to-lipogenic switch during fibrosis resolution. Analysis of human lung tissues and primary human lung fibroblasts indicates that this fate switching is involved in IPF pathogenesis, opening potential therapeutic avenues to treat patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fibroblast aerobic glycolysis is increased by upregulating rate-limiting glycolytic enzymes.
“Fibroblast aerobic glycolysis is increased by upregulating rate-limiting glycolytic enzymes43.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 39 · Cited by 347
- Authors
- El Agha, E., Moiseenko, A., Kheirollahi, V., De Langhe, S., Crnkovic, S., Kwapiszewska, G., Szibor, M., Kosanovic, D., Schwind, F., Schermuly, R. T., Henneke, I., MacKenzie, B., Quantius, J., Herold, S., Ntokou, A., Ahlbrecht, K., Braun, T., Morty, R. E., Günther, A., Seeger, W., & Bellusci, S.
- Affiliations
- Justus-Liebig-Universität Gießen (DE)
- Max Planck Institute for Heart and Lung Research (DE)
- ORCID
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 20
- Issue
- 2
- Pages
- 261-273.e3
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- PMC
- PMC5291816
- OpenAlex
- W2549204323
- Cited by
- 347
- References
- 39
- Citations by year
- 2026: 33 · 2025: 35 · 2024: 54 · 2023: 39 · 2022: 27 · 2021: 42 · 2020: 46 · 2019: 24 · 2018: 30 · 2017: 17
- FWCI
- 21.16
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-04-06)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell stem cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (1R01HL086322-01A2, HL107307, R01HL126732, R01HL132156, SFB TR84 B2, SFB1021 C05)
- March of Dimes Foundation (1-FY15-352)
- Pulmonary Fibrosis Foundation
- Uniklinikum Giessen und Marburg
- Deutsches Zentrum für Lungenforschung
- Cardio-Pulmonary Institute
- European Cooperation in Science and Technology (BM1201)
- Deutsche Forschungsgemeinschaft (BE4443/4-1, BE4443/6-1, CRC1213)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, pulmonary fibrosis, myofibroblasts, fibrosis resolution, fibrosis progression, extracellular matrix deposition, interstitial lung disease
- MeSH terms
- Actins, Animals, Fibroblasts, Humans, Lung, Phenotype, Signal Transduction, Disease Progression, Muscle Development, Myocytes, Smooth Muscle, PPAR gamma, Lipogenesis, Mice, Fibroblast Growth Factor 10, Transforming Growth Factor beta1, Idiopathic Pulmonary Fibrosis, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
